«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 02

Page:

387-391

Research Field:

Publishing date:

Info

Title:

Research progress in targeted prostate biopsy based on mpMRI and PSMA PET/CT

Author(s):

CHEN Jian¹; 2; WU Peng²; HU Wei²; ZHANG Jingliang²; JIAO Jianhua²; MA Shuaijun²; YANG Wenhui¹; CUI Chaochao¹; QIN Weijun²

1.Xi'an Medical University,Shaanxi Xi'an 710021,China;2.Department of Urology,First Affiliated Hospital of Air Force Military Medical University,Shaanxi Xi' an 710032,China.

Keywords:

prostate cancer; multi-parameter magnetic resonance imaging; prostate specific membrane antigen; positron emission tomography computed tomography; prostate biopsy

PACS:

R737.25

DOI:

10.3969/j.issn.1672-4992.2024.02.035

Abstract:

The incidence and mortality of prostate cancer (PCa) are increasing in western developed countries.With the increase of aging population,the improvement of dietary life and the development of social economy,prostate cancer is significantly increasing in China.Early detection,diagnosis and treatment is particularly important for treatment selection.Traditional diagnostic methods,including serum prostate specific antigen (PSA),digital rectal examination (DRE) and prostate biopsy,in which biopsy pathology has always been the gold standard for the diagnosis of prostate cancer.At present,ultrasound-guided biopsy is mainly used in clinic,but there are some shortcomings such as low diagnosis rate and difficult to guide special parts of the prostate.Therefore,to improve the detection efficiency and accuracy,the combination of multi-parameter nuclear magnetic resonance (mpMRI) or PSMA PET/CT with rectal ultrasound targeted biopsy has shown good potential in clinical application.The purpose of this paper is to review the research progress of these two targeted biopsy methods,so as to lay a foundation for improving the rate of early diagnosis and further serving clinical diagnosis.

References:

£Û1£ÝSUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£ÝÀîÐÇ,ÔøÏþÓÂ.ÖйúÇ°ÁÐÏÙ°©Á÷Ðв¡Ñ§Ñо¿½øÕ¹£ÛJ£Ý.Ö×Áö·ÀÖÎÑо¿,2021,48(01):98-102. LI X£¬ZENG XY.Advances in epidemiology of prostate cancer in China£ÛJ£Ý.Cancer Research on Prevention and Treatment,2021,48(01):98-102.
£Û3£ÝPANG C,GUAN Y,LI H,et al.Urologic cancer in China£ÛJ£Ý.Jpn J Clin Oncol,2016,46(6):497-501.
£Û4£ÝDONATO P,MORTON A,YAXLEY J,et al.68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy:Is 68Ga-PSMA PET/CT guided biopsy the future£ÛJ£Ý.European Journal of Nuclear Medicine and Molecular Imaging,2020,47(8):1843-1851.
£Û5£ÝÅ£ Ä,²Ü»Ô.MRIÁªºÏ¾­Ö±³¦³¬Éù°ÐÏò´©´ÌÔÚÇ°ÁÐÏÙ°©ÖеÄÓ¦ÓãÛJ£Ý.Ó°Ïñ¿ÆѧÓë¹â»¯Ñ§,2023,41(1):6-10. NIU B,CAO H.Application of MRI combined with transrectal ultrasound targeted puncture in the diagnosis of prostate cancer£ÛJ£Ý.Imaging Science and Photochemistry,2023,41(1):6-10.
£Û6£ÝNGUYEN-NIELSEN M,BORRE M.Diagnostic and therapeutic strategies for prostate cancer£ÛJ£Ý.Semin Nucl Med,2016,46(6):484-490.
£Û7£ÝLITWIN MS,TAN HJ.The diagnosis and treatment of prostate cancer:a review£ÛJ£Ý.JAMA,2017,317(24):2532-2542.
£Û8£ÝOSSES DF,REMMERS S,SCHRODER FH,et al.Results of prostate cancer screening in a unique cohort at 19yr of follow-up£ÛJ£Ý.Eur Urol,2019,75(3):374-377.
£Û9£ÝEKLUND M,JADERLING F,DISCACCIATI A,et al.MRI-targeted or standard biopsy in prostate cancer screening£ÛJ£Ý.N Engl J Med,2021,385(10):908-920.
£Û10£ÝMOHLER JL,ANTONARAKIS ES,ARMSTRONG AJ,et al.Prostate cancer,version 2.2019,NCCN clinical practice guidelines in oncology£ÛJ£Ý.Journal of the National Comprehensive Cancer Network,2019,17(5):479-505.
£Û11£ÝMOHLER JL,ARMSTRONG AJ,BAHNSON RR,et al.Prostate cancer,version 1.2016£ÛJ£Ý.Journal of the National Comprehensive Cancer Network:JNCCN,2016,14(1):19-30.
£Û12£ÝNORDSTR¦ZM T,DISCACCIATI A,BERGMAN M,et al.Prostate cancer screening using a combination of risk-prediction,MRI,and targeted prostate biopsies (STHLM3-MRI):a prospective,population-based,randomised,open-label,non-inferiority trial£ÛJ£Ý.The Lancet Oncology,2021,22(9):1240-1249.
£Û13£ÝKLOTZ L,CHIN J,BLACK PC,et al.Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naive men at risk for prostate cancer:a phase 3 randomized clinical trial£ÛJ£Ý.JAMA Oncol,2021,7(4):534-542.
£Û14£ÝLENFANT L,BARRET E,ROUPRET M,et al.Transperineal prostate biopsy is the new black:what are the next targets£ÛJ£Ý.Eur Urol,2022,82(1):3-5.
£Û15£ÝXUE J,QIN Z,CAI H,et al.Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer:a meta-analysis and trial sequential analysis£ÛJ£Ý.Oncotarget,2017,8(14):23322-23336.
£Û16£ÝMOTTET N,VANDENBERGH RCN,BRIERS E,et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update.Part 1:Screening,diagnosis,and local treatment with curative intent£ÛJ£Ý.Eur Urol,2021,79(2):243-262.
£Û17£ÝSANDA MG,CADEDDU JA,KIRKBY E,et al.Clinically localized prostate cancer:AUA/ASTRO/SUO guideline.Part I:Risk stratification,shared decision making,and care options£ÛJ£Ý.J Urol,2018,199(3):683-690.
£Û18£ÝBORGHESI M,AHMED H,NAM R,et al.Complications after systematic,random,and image-guided prostate biopsy£ÛJ£Ý.Eur Urol,2017,71(3):353-365.
£Û19£ÝBASS EJ,PANTOVIC A,CONNOR MJ,et al.Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate:a systematic review and meta-analysis£ÛJ£Ý.Prostate Cancer Prostatic Dis,2022,25(2):174-179.
£Û20£ÝLOEB S,BJURLIN MA,NICHOLSON J,et al.Overdiagnosis and overtreatment of prostate cancer£ÛJ£Ý.Eur Urol,2014,65(6):1046-1055.
£Û21£ÝWETTERAUER C,TROTSENKO P,MATTHIAS MO,et al.Diagnostic accuracy and clinical implications of robotic assisted MRI-US fusion guided target saturation biopsy of the prostate£ÛJ£Ý.Sci Rep,2021,11(1):20250.
£Û22£ÝJOHNSON LM,TURKBEY B,FIGG WD,et al.Multiparametric MRI in prostate cancer management£ÛJ£Ý.Nat Rev Clin Oncol,2014,11(6):346-353.
£Û23£ÝAHMED HU,EL-SHATERBOSAILY A,BROWN LC,et al.Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS):a paired validating confirmatory study£ÛJ£Ý.The Lancet,2017,389(10071):815-822.
£Û24£ÝKUMAR V,BORA GS,KUMAR R,et al.Multiparametric (mp) MRI of prostate cancer£ÛJ£Ý.Prog Nucl Magn Reson Spectrosc,2018,105:23-40.
£Û25£ÝGOLDBERG H,AHMAD AE,CHANDRASEKAR T,et al.Comparison of magnetic resonance imaging and transrectal ultrasound informed prostate biopsy for prostate cancer diagnosis in biopsy naive men:a systematic review and Meta-analysis£ÛJ£Ý.J Urol,2020,203(6):1085-1093.
£Û26£ÝCORNUD F,BROLIS L,DELONGCHAMPS NB,et al.TRUS-MRI image registration:a paradigm shift in the diagnosis of significant prostate cancer£ÛJ£Ý.Abdom Imaging,2013,38(6):1447-1463.
£Û27£ÝHOFFMANN MA,WIELER HJ,JAKOBS FM,et al.Diagnostic significance of multiparametric MRI combined with US-fusion guided biopsy of the prostate in patients with increased PSA levels and negative standard biopsy results to detect significant prostate cancer-Correlation with the Gleason score.Korrelation mit dem Gleason score£ÛJ£Ý.Nuklearmedizin,2017,56(4):147-155.
£Û28£ÝLI D,LIU Y,LI Z,et al.Magnetic resonance imaging-transrectal ultrasound cognitive fusion targeted biopsy on the diagnosis of prostate cancer:a research of 614 cases in single center£ÛJ£Ý.J Biomedical Eng,2020,37(2):225-229.
£Û29£ÝWEGELIN O,EXTERKATE L,VANDERLEEST M,et al.The FUTURE trial:A multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies£ÛJ£Ý.Eur Urol,2019,75(4):582-590.
£Û30£ÝKASIVISVANATHAN V,STABILE A,NEVES JB,et al.Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer:A systematic review and Meta-analysis£ÛJ£Ý.Eur Urol,2019,76(3):284-303.
£Û31£ÝÖìÔÆ¿ª,³ÂÑÇÇà,ÖÓܽÈØ,µÈ.¾­Ö±³¦³¬Éù/¶à²ÎÊý´Å¹²ÕñÈںϰÐÏò´©´ÌÔÚÁÙ´²ÏÔÖøÇ°ÁÐÏÙ°©Õï¶ÏÖеļÛÖµ£ÛJ£Ý.Öлª³¬ÉùÓ°ÏñѧÔÓÖ¾,2021,30(02):145-150. ZHU YK,CHEN YQ,ZHONG FR,et al.Transrectal ultrasound/multiparametric magnetic resonance imaging fusion targeted biopsy for the clinically significant prostate cancer detection £ÛJ£Ý.Chinese Journal of Ultrasonography,2021,30(02):145-150.
£Û32£ÝAHDOOT M,WILBUR AR,REESE SE,et al.MRI-targeted,systematic,and combined biopsy for prostate cancer diagnosis£ÛJ£Ý.N Engl J Med,2020,382(10):917-928.
£Û33£Ý¸¶ÕñÓî,ËïÀû¹ú,ÕŸë,µÈ.MRI/TRUSÈÏÖªÈÚºÏÁªºÏ12Õëϵͳ¾­»áÒõÇ°ÁÐÏÙ´©´Ì»î¼ìµÄÁÙ´²Ñо¿£ÛJ£Ý.ÖлªÄпÆѧÔÓÖ¾,2021,27(05):421-425. FU ZY,SUN LG,ZHANG G,et al.MRI/TRUS cognitive fusion combined with 12-core systematic transperineal prostate biopsy for the diagnosis of clinically significant prostate cancer:A report of 208 cases£ÛJ£Ý.National Journal of Andrology,2021,27(05):421-425.
£Û34£ÝÕÅ·«,×óÇ¿,»ÆÒã,µÈ.ºË´Å¹²ÕñÓ볬ÉùÈںϳÉÏñÒýµ¼ÏÂÇ°ÁÐÏÙ°ÐÏò´©´Ì¶ÔGleasonÆÀ·Ö¡Ý7·ÖÇ°ÁÐÏÙ°©¼ì³öµÄÁÙ´²ÒâÒå£ÛJ£Ý.ÖйúÄпÆѧÔÓÖ¾,2018,32(3):33-36,46. ZHANG F,ZUO Q,HUANG Y,et al.The clinical significance of multiparametric magnetic resonance imaging/transrectal ultrasound fusion targeted biopsy in detection of prostate cancer with Gleason score¡Ý7£ÛJ£Ý.Chinese Journal of Andrology,2018,32(3):33-36,46.
£Û35£ÝGAZIEV G,WADHWA K,BARRETT T,et al.Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool£ÛJ£Ý.BJU Int,2016,117(1):80-86.
£Û36£ÝPANEBIANCO V,BARCHETTI G,SIMONE G,et al.Negative multiparametric magnetic resonance imaging for prostate cancer:What's next£ÛJ£Ý.Eur Urol,2018,74(1):48-54.
£Û37£ÝBOROFSKY S,GEORGE AK,GAUR S,et al.What are we missing? False-negative cancers at multiparametric MR imaging of the prostate£ÛJ£Ý.Radiology,2018,286(1):186-195.
£Û38£ÝHOFFMANN MA,WIELER HJ,BAUES C,et al.The impact of 68Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer£ÛJ£Ý.Urology,2019,130:1-12.
£Û39£ÝÁÖЦÓî,ËÎΰ,ëºêêÍ,µÈ.(68)Ga-PSMA-617 PET/CTÔÚ³õÕïÇ°ÁÐÏÙ°©Ô¶´¦×ªÒÆÔî¼ì²âÖеÄÓ¦ÓÃʱ»ú£ÛJ£Ý.ÏÖ´úÃÚÄòÍâ¿ÆÔÓÖ¾,2019,24(03):205-209. LIN XY,SONG W,MAO HH,et al.The best time point in the application of 68Ga-PSMA-617 PET/CT for distant meta-static lesions of newly diagnosed prostate cancer£ÛJ£Ý.Journal of Modern Urology,2019,24(03):205-209.
£Û40£Ý¶ÎСÒÕ.Ç°ÁÐÏÙ°©PSMA PET/CTÏÔÏñµÄÓ¦ÓÃÏÖ×´Óë˼¿¼£ÛJ£Ý.Î÷°²½»Í¨´óѧѧ±¨£¨Ò½Ñ§°æ£©,2022,43(2):163-167. DUAN XY.Current status and thoughts of PSMA PET/CT imaging application for prostate cancer£ÛJ£Ý.Journal of Xi'an Jiaotong University(Medical Sciences),2022,43(2):163-167.
£Û41£ÝÀîÓî.ÒÔPSMAΪ°ÐµãµÄÖ×Áö·Ö×ÓÓ°ÏñÕï¶ÏÓëÃâÒßÖÎÁƳõ²½Ñо¿£ÛD£Ý.Î÷°²£º¿Õ¾ü¾üÒ½´óѧ,2019. LI Y.Preliminary study on molecular imaging diagnosis and immunotherapy of tumors targeting PSMA£ÛD£Ý.Xi'an:Air Force Medical University,2019.
£Û42£ÝJAIN H,SOOD R,FARIDI MS,et al.Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy:a prospective study£ÛJ£Ý.Cent European J Urol,2021,74(3):315-320.
£Û43£ÝMA L,ZHANG WC,HAO YX.Current state of prostate-specific membrane antigen PET/CT imaging-targeted biopsy techniques for detection of clinically significant prostate cancer£ÛJ£Ý.J Med Imaging Radiat Oncol,2022,66(6):776-780.
£Û44£ÝÍôÀÚ,ÕÔ×Ó³¼,¹ûºê·å,µÈ.È«Ï¢Ó°ÏñÔÚ¾­»áÒõÇ°ÁÐÏÙ°ÐÏò´©´ÌÖеÄÓ¦ÓãÛJ£Ý.ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾,2022,43(2):111-115. WANG L,ZHAO ZC,GUO HF,et al.Application of holographic image in transperineal prostate targeted biopsy£ÛJ£Ý.Chinese Journal of Urology,2022,43(2):111-115.
£Û45£ÝZHANG LL,LI WC,XU Z,et al.(68)Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy:a prospective randomized single-centre study£ÛJ£Ý.Eur J Nucl Med Mol Imaging,2021,48(2):483-492.
£Û46£ÝÎäÅô,Õž°Á¼,Âí˧¾ü,µÈ.(68)Ga-PSMA-PET/CT°ÐÏòÈںϴ©´ÌÔÚÇ°ÁÐÏÙÖظ´´©´Ì»î¼ìÖеÄÓ¦ÓÃÑо¿£ÛJ£Ý.ÁÙ´²ÃÚÄòÍâ¿ÆÔÓÖ¾,2021,36(12):927-931. WU P,ZHANG JL,MA SJ,et al.Application of 68Ga-PSMA-PET/CT targeted fusion repeat puncture in biopsy of prostate£ÛJ£Ý.Journal of Clinical Urology,2021,36(12):927-931.
£Û47£ÝÁÖ¹úÎÄ,´÷²¨,Ò¶¶¨Î°,µÈ.¶à²ÎÊý´Å¹²ÕñºÍ(68)Ga-PSMA PET/CTͼÏñ¼ä½ÓÈÚºÏÒýµ¼Ç°ÁÐÏÙ°ÐÏò´©´Ì»î¼ìµÄÁÙ´²·ÖÎö£ÛJ£Ý.ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾,2022,43(07):484-489. LIN GW,DAI B,YE DW,et al.Clinical analysis of prostate targeted biopsy guided by multiparametric magnetic resonance imaging and 68Ga-PSMA PET/CT image fusion£ÛJ£Ý.Chinese Journal of Urology,2022,43(07):484-489.
£Û48£ÝJIAO J,KANG F,ZHANG J,et al.Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET/CT:a real-world study£ÛJ£Ý.Theranostics,2021,11(17):8396-8411.

Memo

Memo:

National Natural Science Foundation of China(No.81172146£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð×ÊÖúÏîÄ¿£¨±àºÅ£º81172146£©

Common functions

Last Update: 1900-01-01